

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A composition for treating or preventing a flavivirus or pestivirus infection, comprising:
a Jab1 (Jun-activation binding protein 1) protein; and
a pharmaceutically acceptable carrier.

2. (original) The composition as set forth in claim 1, wherein the Jab1 protein has an amino acid sequence designated as SEQ ID No. 2.

3. (original) The composition as set forth in claim 1, wherein the Jab1 protein is encoded by a nucleotide sequence designated as SEQ ID No. 1.

4. (withdrawn) A composition for treating or preventing a flavivirus or pestivirus infection, comprising a nucleic acid having a nucleotide sequence coding for a Jab1 protein.

5. (withdrawn) The composition as set forth in claim 4, wherein the nucleic acid having the nucleotide sequence coding for the Jab1 protein is a recombinant vector having a nucleotide sequence coding for an amino acid sequence designated as SEQ ID No. 2.

6. (withdrawn) The composition as set forth in claim 4, wherein the nucleic acid having the nucleotide sequence coding

for the Jab1 protein is a recombinant vector having a nucleotide sequence designated as SEQ ID No. 1.

7. (withdrawn) The composition as set forth in claim 5 or 6, wherein the recombinant vector is a recombinant viral vector.

8. (withdrawn) The composition as set forth in claim 7, wherein the recombinant viral vector is selected from among recombinant retrovirus, adenovirus, adeno-associated virus and herpes simplex virus.

9. (withdrawn) A composition for treating or preventing a flavivirus or pestivirus infection, comprising a recombinant virus expressing a Jab1 protein.

10. (withdrawn) The composition as set forth in claim 9, wherein the recombinant vector expressing the Jab1 protein is a recombinant virus expressing a Jab1 protein having an amino acid sequence designated as SEQ ID No. 2.

11. (withdrawn) The composition as set forth in claim 9, wherein the recombinant vector expressing the Jab1 protein is a recombinant virus expressing a Jab1 protein encoded by a nucleotide sequence designated as SEQ ID No. 1.

12. (withdrawn) The composition as set forth in claim 9, wherein the recombinant vector is selected from among adenovirus, adeno-associated virus and herpes simplex virus.

13. (withdrawn) The composition as set forth in claim 12, wherein the recombinant vector is selected from among retrovirus and adenovirus.

14. (currently amended) The composition as set forth in ~~any one of claim[[s]] 1, 4 and 9,~~ wherein the infection is a flavivirus infection.

15. (currently amended) The composition as set forth in claim ~~14~~ 1, wherein the flavivirus is West Nile virus.

16. (currently amended) The composition as set forth in ~~any one of claim[[s]] 1, 4 and 9,~~ wherein the infection is associated with fever, rash, bleeding, jaundice, arthralgia, myalgia, encephalitis or meningitis.

17. (withdrawn) A method of screening a compound stimulating expression of a Jab1 protein, comprising:

- (a) culturing a cell expressing the Jab1 protein;
- (b) contacting the cell cultured at (a) with candidate compounds for stimulating expression of the Jab1 protein;
- (c) comparing an expression level of the Jab1 protein at (b) with that in a control not contacted with the candidate compounds; and
- (d) identifying a compound increasing expression levels of the Jab1 protein.

18. (withdrawn) A method of screening a compound stimulating interaction between a Jab1 protein and a capsid (Cp) protein, comprising:

(a) culturing a cell transformed with both a recombinant vector expressing the Jab1 protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus;

(b) contacting the cell cultured at (a) with candidate compounds for stimulating interaction between the Jab1 protein and the Cp protein;

(c) comparing an expression level of the Cp protein at (b) with that in a control not contacted with the candidate compounds; and

(d) identifying a compound reducing expression levels of the Cp protein.

19. (withdrawn) The method as set forth in claim 17 or 18, wherein the comparison of expression levels at (c) is carried out in protein or mRNA levels.

20. (withdrawn) The method as set forth in claim 19, wherein the comparison of expression levels is carried out by an immunoassay method.

21. (withdrawn) The method as set forth in claim 19, wherein the comparison of expression levels is carried out in mRNA levels by RT-PCT (Reverse Transcription-Polymerization Chain Reaction).

22. (new) The composition as set forth in claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a binder, a lubricant, a disintegrator,

an excipient, a solubilizing agent, a dispersing agent, a stabilizing agent, a suspending agent, a pigment, an aromatic, a buffering agent, a preservative, an analgesic, a solubilizing agent, a tonic adjusting agent, a stabilizing agent, a base, an excipient, a lubricant and a preservative.

23. (new) The composition as set forth in claim 1, wherein the compositions is selected from the group consisting of a tablet, a troche, a capsule, an elixir, a suspension, a syrup, a wafer, and a unit dosage form.

24. (new) The composition as set forth in claim 23, wherein the unit dosage form is selected from the group consisting of a multidose container and an ampoule as a single-dose dosage form.